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after the end of the radiation treatment, which required the 
use of high dose-opioid and gabaergic pain relievers, 
chronically. In fact, this was the main factor to consider in 
our study. Local control was analized too. 
 
Results: Eight patients were treated with 3 Gy /fraction, four 
of them suffered neuropathic pain in radiation field that 
required chronic drug treatment. (RR 50%). None of the five 
patients treated with the 2 Gy per fraction technique had 
neuropathic pain in legs. 
 
Conclusion: Our preliminary results indicate that the 2 Gy 
per fraction treatment avoids the onset of neuropathic pain 
after the radiation treatment. Althoug the patient 
recruitment was low, we can afirm that both radiation 
techniques were very useful in the classic KS local control. 
The 2 Gy per fraction treatment was not associated to 
neuropathic pain, compared with the hypofractioned 
radiation treatment. 
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Purpose or Objective: To evaluate the results of stereotactic 
ablative radiotherapy (SABR) in selected metastatic sarcomas 
patients 
 
Material and Methods: Outcomes of 21 consecutive 
metastatic STS patients (32 consecutive lesions) receiving 
SABR between 2012 and 2015 at our center were 
retrospectively analyzed.  
 
Results: Most patients (85%) had a performance status of 0-1 
and the median age at treatment was 62.4 years. Metastases 
treated were localized in lung (37,5%), brain (37,5%), liver 
(9,5%), soft-tissue (12,5%) and pancreas (3%). The median 
size of the treated lesion was 2.1 cm. The median biologic 
equivalent dose delivered was 120 Gy (range, 52.7-213.8 Gy) 
delivered in a median number of 5 fractions (range, 1-13). 
The majority of patients received systemic agents prior SABR 
(16/21). With a median follow-up of 18 months, the 2 years 
local control rate was 86% (CI 95%: 51-100%; median: not 
reached), with four progressives lesions. Only one patient 
experienced a grade 3 toxicity consisting of an ear bleeding. 
Two years overall survival and progression free survival rates 
were respectively 72% (CI 95%: 47-96%) and 39% (CI 95%: 15-
63%). 
 
Conclusion: SABR in metastatic sarcoma seems to be an 
effective tool in local control that might be used as an 
alternative to other local treatments in highly selected 
patients. 
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Purpose or Objective: MRI characteristics and extent of 
disease in glioma is important for surgical planning. However, 
MRI may not adequately guide biopsy location in non-
enhancing tumors. Furthermore, post-radiation changes are 
difficult to differentiate from progressive tumor. We 
previously demonstrated the PET tracer 3,4-dihydroxy-6-
[18F]fluoro-l-phenylalanine(FDOPA) has a sensitivity for 
gliomas and may improve neurosurgical planning in adults. 
This study evaluates the utility of FDOPA-PET/CT imaging in 
biopsy and resection planning in pediatric patients. 
 
Material and Methods: MR/CT and FDOPA-PET/CT images 
were obtained in 5 patients with primary or recurrent 
malignant gliomas. Regions of interest were defined based on 
areas of MRI contrast enhancement (CE) and FDOPA uptake to 
include both concordant (MRI-CE and high-FDOPA) and 
disconcordant (MRI-non-CE and high-FDOPA, MRI-CE and low 
FDOPA) regions. Ratios of maximum tumor SUV (SUVmax) 
normalized to mean SUV (SUVmean) of normal brain tissue 
(T/N) were determined using the SUVmax from each biopsy 
coordinate and the SUVmean from contralateral normal brain 
tissue.  
 
Results: The FDOPA-PET images guided biopsy site selection 
in four patients. One patient with contrast enhancement in 
an eloquent location near a region of prior radiotherapy did 
not undergo biopsy after FDOPA-PET failed to show increased 
uptake. Average tumor SUVmax was 2.135 (range 2.92-1.27), 
and the T/N average T/N ratio was 1.6 (range 1.92-1.18). 
Biopsies within the region of highest uptake were performed 
in 3 patients and were consistent with Grade III or Grade IV, 
despite lack of contrast enhancement 1 patient. In one 
patient, SUVmax was in an eloquent region of thalamus and 
was deemed an unsafe location for biopsy. Biopsy from an 
adjacent region revealed infiltrating glioma, non-diagnostic 
for grade. Regions of increased FDOPA uptake extended 
beyond those identified with MRI in two patients.  
 
Conclusion: FDOPA-PET imaging appears to have utility in 
guiding biopsy region selection and may assist with 
identifying regions of higher-grade disease in pediatric 
patients with astrocytomas. 
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Purpose or Objective: Respiration-induced organ motion is 
one of the main contributors to intrafractional motion, 
limiting the maximum achievable accuracy in radiation 
therapy (RT). Knowledge on respiration-induced organ motion 
in children during RT is extremely scarce and urgently 
needed for better definitions of abdominal and thoracic 
safety margins. It also allows to assess whether developments 
and introduction of child-friendly breathing exercises and/or 
coaching during the treatment course could have an added 
value to control and minimize respiration-induced organ 
motion. Therefore, the aim of this study is to investigate how 
respiration influences the diaphragmatic motion, as 
indicative of organ motion in the abdomen and thorax, during 
image guided RT (IGRT) in children and to find possible 
relationships with age and height. In addition, we 
investigated trends in the respiration-induced diaphragmatic 
motion during the treatment course. 
 
Material and Methods: This retrospective study consisted of 
15 patients with a mean age of 10.6 years (range 2.2-16.9 
years) and a mean height of 140 cm (range 90–167 cm), 
treated at our institute between 2006 and 2015, for whom for 
setup correction routinely acquired evaluable images of the 
thorax were available. This amounted to a total of 15 
reference CT (refCT) scans and 86 Cone Beam CT (CBCT) 
scans. CBCTs were reconstructed for the inhale and exhale 
respiratory phases and registered to the refCT using Elekta 
XVI software. First, the vertebrae were aligned. 
Subsequently, the diaphragm was manually aligned in cranio-
caudal (CC) direction only. The result yields the mean peak-
to-peak (PP) motion (i.e., magnitude of motion) of the 
diaphragm in the CC direction, derived from registration 
outcomes of the inhale and exhale CBCTs to the refCT. 
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Possible time trends were investigated by analyzing the 
derived PP motion from daily CBCTs as a function of 
treatment day. The reproducibility of the PP motion was 
measured as the standard deviation (SD) over the mean PP 
motion per patient. We used a linear regression model to 
analyse the relationship between these outcomes and age 
and height.  
 
Results: Over all patients, PP motion was on average 8.6 mm 
(range 4-15 mm) and varied largely within and between 
patients. Time trends differed between patients. PP motion 
correlated with age and height (p<0.05). PP motion increased 
by 0.42 mm for every yearly increase in patients’ age and for 
every 1 cm increase in height the PP motion increased 0.07 
mm (Figure 1). The SD ranged from 1-3.7 mm and correlated 
with age and height (p<0.05) (Figure 1). 
 
 
 
Conclusion: Respiration-induced diaphragmatic motion in 
children during IGRT is correlated with age and height, 
however irregular breathing patterns were found. PP motion 
was variable throughout the treatment. Therefore, 
introducing child-friendly breathing exercises and/or 
coaching techniques may be beneficial to minimize PP motion 
and to enhance its reproducibility.  
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Purpose or Objective: Second malignant neoplasms (SMNs) 
are a concern in survivors of childhood cancer. Chemotherapy 
forms the mainstay of treatment for acute lymphoblastic 
leukaemia (ALL), but radiotherapy has a role in certain 
situations. As both chemotherapy and radiotherapy can be 
carcinogenic, patients treated with both modalities may be 
at a higher risk of SMNs. This study aims to investigate the 
incidence of SMNs in patients treated with both 
chemotherapy and radiotherapy at KK Women's and Children's 
Hospital, Singapore. 
 
Material and Methods: We performed a retrospective review 
of ALL patients treated in the largest maternal and children's 
hospital in Singapore. Children aged 16 years and below 
diagnosed with ALL from 1993 to 2014 were identified in the 
Childhood Cancer Registry. Manual and electronic medical 
records were reviewed for information on demographics, 
management and SMNs. 
 
Results: A total of 64 patients treated with both 
chemotherapy and radiotherapy were identified. Seventeen 
(26.6%) were female and 47 (73.4%) were male. The median 
follow-up was 9.2 years (range, 1.1-22.0 years). The median 
age at diagnosis was 5.3 years (range, 0.3-14.6 years). The 
median age at which radiotherapy was given was 6.6 years 
(range, 2.9-15.4 years).  
SMNs were noted in 3 of 64 (4.7%) patients. Two of 3 patients 
had a SMN within the radiation field (both cranial). The 
histological diagnoses were basal cell carcinoma and cerebral 
PNET. The remaining patient had an ovarian immature 
teratoma outside the radiation field. The median latency 
period was 9.4 years (range, 8.3-13.3 years) from date of 
diagnosis to development of SMN. The estimated 10-year 
cumulative incidence was 4.3%, 95% CI [0.01, 0.13] using a 
competing risks analysis.  
Radiotherapy data was available in 63 patients. Fifty-one of 
63 (81.0%) received cranial irradiation, of which 3 (5.9%) also 
received spinal irradiation. Total body irradiation was 
performed in 20 of 63 (31.7%), and testicular irradiation in 17 
of 63 (27.0%) patients. The orbit was targeted in 3 of 63 
(4.8%) patients. 
 
Conclusion: Long term survivors of ALL treated with both 
chemotherapy and radiotherapy may have a significant risk of 
second malignant neoplasms, which may occur years after 
the initial diagnosis. 
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Purpose or Objective: An intensity-modulated radiation 
therapy technique for craniospinal irradiation (IMRT-CSI) 
delivered on the Tomotherapy unit has been used at our 
centre since 2008. Defining and prioritizing dose constraints 
to target and organs at risk (OAR) are time-consuming. To 
facilitate and standardize the planning process, we 
developed a dose-volume histogram (DVH) registry and tested 
its usefulness with two cohorts of patients treated to 
different doses of CSI.  
 
Material and Methods: The registry consists of a back-end 
MySQL database and front-end webpages that are served via 
a web-server internal to the clinic. Approved plans are added 
to the DVH registry via a filter that standardizes the names of 
the OARs. Dose constraints for planning are established based 
on previous aggregate data and planners graphically compare 
DVH data for a new treatment plan with existing aggregate 
data without submitting the new data to the registry. We 
evaluated two cohorts of IMRT-CSI patients: (1) CSI dose 36 
Gy in 20 fractions and (2) CSI dose 23.4 Gy in 13 fractions and 
compared the findings with an earlier cohort of patients that 
were planned before we started using the registry. 
 
Results: Eighteen patients, age 3 to 17 years, were included 
in the registry. Eleven were treated to a dose of 36 Gy in 20 
fractions and seven to a dose of 23.4 Gy in 13 fractions. Most 
(56%) had medulloblastoma. Significantly smaller variations 
were achieved for OAR for patients treated at 36 Gy using the 
DVH registry compared with patients in the earlier cohort, 
making the registry a very useful tool for the treating team. 
V20 were lower for all OARs except the trachea. 
 
Conclusion: The results confirm that the DVH registry 
standardizes the planning process of IMRT-CSI patients. We 
will use constraints obtained from the 7 patients treated at 
23.4 Gy to start planning new cases and evaluate the benefit 
of our DVH registry for this regimen. 
 
 
 
 
 
